Search Results

Secarna is pleased to announce that the Company’s partner Lipigon Pharmaceuticals AB (“Lipigon”) has advanced their lead candidate, Lipisense , into a phase 1 clinical study.

Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, today announced that the company has expanded its agreement with the Shanghai STAR listed company HitGen Inc. (”HitGen”) to include a second novel target. With joint efforts, the aim is to develop a treatment for cardiometabolic disease.

Secarna Pharmaceuticals GmbH & Co. KG (“Secarna”), a biopharmaceutical company focusing on the discovery and development of next generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAplusTM platform, today announced that the Company signed a Research, Development and Transfer Agreement with Lipigon Pharmaceuticals AB (“Lipigon”).

Secarnas partner Lipigon has selected an LNAplus TM ASO candidate targeting ANGPTL4, called Lipisense, which has shown unique efficacy in reducing lipid triglycerides in experimental disease models and is now entering pre-clinical safety development High levels of plasma lipids triglycerides are associated with a plethora of lipid-related diseases with yet unmet clinical treatment needs

It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

Secarna Pharmaceuticals announced that the Company has entered into an research agreement with a global pharmaceutical company to support research and discovery in the field of oncology.